Market Overview

Exelixis Presents Positive COMETRIQ Clinical Trial Data in Patients with Progressive, Metastatic Medullary Thyroid Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--

Exelixis, Inc. (NASDAQ: EXEL) today announced the presentation of
additional data from clinical trials of COMETRIQ™ (cabozantinib) in
patients with progressive, metastatic medullary thyroid cancer (MTC).
The data were presented this weekend at the 2013 Annual Meeting of the
American Society of Clinical Oncology (ASCO). Long-term follow-up of a
phase 1 trial (Abstract #6090) shows that 30% of progressive, metastatic
MTC patients treated with COMETRIQ experienced disease control (DC) and
have remained progression-free for more than 2 years. A separate
presentation (Abstract #6000) reports data from the prospective analysis
of RET mutational status and retrospective ad hoc analysis of RAS
mutational status of patients in EXAM, Exelixis' phase 3 pivotal trial
of COMETRIQ in progressive, metastatic MTC. These data show

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (EXEL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters